Biotech Informa is the news portal and database where industry and suppliers meet...
The Biotech Database lists in detail over 10,000 Biotech companies and resource suppliers characterised by speciality and geographical location, these include listings for biotech companies, biotech suppliers, biotech finance and biotech R&D companies.
Biotech Informa is a unique database of Biotech companies, the Biotech database covers everything from biotech companies and biotech suppliers to biotech finance and biotech R&D companies.
Our news service brings you up to the minute information about developments in the Biotech Industry including new products, clinical data, mergers and acquisitions as well as changes in regulations etc.
We keep you up to date with a worldwide list of key Biotechnology conferences, courses and meetings. We give you the opportunity to showcase your products and services to your target audience.
The Biotech databases unique feature is the ablility, once you are registered, to make your own entry and change it whenever required from your computer so the information is always up to date.
This is the web portal the Biotech Industry and all who wish to provide resources has been needing.
New Pfizer Pipeline Shows Progress & Growth In Biologics
Pfizer Inc. has provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development.
“This pipeline of investigational medicines represents the strong future of Pfizer,” said Martin Mackay, president, PharmaTherapeutics Research and Development. “Since the closing of the Wyeth transaction late last year, we have made strategic decisions about our R&D resources, global footprint and high-priority projects. Our focus now turns to delivery of these health solutions for patients around the world.”
“Through the acquisition of Wyeth, Pfizer has become a leading biotherapeutics company, and we are well positioned to pioneer the next generation of high-potential medicines,” said Mikael Dolsten, president, BioTherapeutics Research and Development.
